CA2511482A1 - Methode et systeme de detection de maladies au moyen de combinaisons de marqueurs - Google Patents

Methode et systeme de detection de maladies au moyen de combinaisons de marqueurs Download PDF

Info

Publication number
CA2511482A1
CA2511482A1 CA002511482A CA2511482A CA2511482A1 CA 2511482 A1 CA2511482 A1 CA 2511482A1 CA 002511482 A CA002511482 A CA 002511482A CA 2511482 A CA2511482 A CA 2511482A CA 2511482 A1 CA2511482 A1 CA 2511482A1
Authority
CA
Canada
Prior art keywords
marker
markers
panel
function
value
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002511482A
Other languages
English (en)
Inventor
Joseph Michael Anderberg
Kenneth F. Buechler
Paul H. Mcpherson
Howard J. Kirchick
Jeffrey R. Dahlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alere San Diego Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/331,127 external-priority patent/US20040126767A1/en
Priority claimed from US10/410,572 external-priority patent/US20040121350A1/en
Application filed by Individual filed Critical Individual
Publication of CA2511482A1 publication Critical patent/CA2511482A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Medical Treatment And Welfare Office Work (AREA)

Abstract

La présente invention concerne des méthodes et un système permettant de diagnostiquer des maladies ou des troubles. Dans un aspect particulier, un procédé de détermination d'un panel consiste à calculer une réponse de panel pour chaque patient dans un groupe de patients malades et dans un groupe de patients non malades. La réponse du panel constitue une fonction de la valeur de chacun des marqueurs dans un panel de marqueurs. Ladite méthode consiste ensuite à calculer une valeur pour une fonction objective qui indique l'efficacité du panel. Les étapes de calcul d'une réponse de panel pour chaque patient et de calcul d'une valeur pour une fonction objective sont itérées par variation d'au moins un des paramètres relatifs à la fonction de réponse de panel et à une direction de chaque marqueur afin de faciliter l'optimisation de la fonction objective. Cette dernière peut constituer une mesure d'un recoupement de réponses de panel des patients malades et des patients non malades. La contribution de chaque marqueur à la fonction objective peut être déterminée, et la taille du panel peut être réduite par élimination des marqueurs les plus dérisoires. Ainsi, peuvent être déterminés un panel optimal de marqueurs et une fonction de réponse de panel optimal pour le diagnostic d'une maladie ou d'un trouble.
CA002511482A 2002-12-24 2003-12-23 Methode et systeme de detection de maladies au moyen de combinaisons de marqueurs Abandoned CA2511482A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US43639202P 2002-12-24 2002-12-24
US60/436,392 2002-12-24
US10/331,127 2002-12-27
US10/331,127 US20040126767A1 (en) 2002-12-27 2002-12-27 Method and system for disease detection using marker combinations
US10/410,572 2003-04-08
US10/410,572 US20040121350A1 (en) 2002-12-24 2003-04-08 System and method for identifying a panel of indicators
PCT/US2003/041426 WO2004058055A2 (fr) 2002-12-24 2003-12-23 Methode et systeme de detection de maladies au moyen de combinaisons de marqueurs

Publications (1)

Publication Number Publication Date
CA2511482A1 true CA2511482A1 (fr) 2004-07-15

Family

ID=32685981

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002511482A Abandoned CA2511482A1 (fr) 2002-12-24 2003-12-23 Methode et systeme de detection de maladies au moyen de combinaisons de marqueurs

Country Status (4)

Country Link
EP (1) EP1588159A4 (fr)
AU (1) AU2003300407A1 (fr)
CA (1) CA2511482A1 (fr)
WO (1) WO2004058055A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
WO2005048823A2 (fr) * 2003-11-17 2005-06-02 Janssen Pharmaceutica N.V. Modelisation d'une reponse inflammatoire systemique a une infection
EP1628136A1 (fr) * 2004-08-19 2006-02-22 B.R.A.H.M.S. Aktiengesellschaft Procédé diagnostic pour des maladies utilisant la copeptin
US20060292647A1 (en) * 2004-12-03 2006-12-28 Green Lawrence R Reflex supplemental testing - A rapid, efficient and highly accurate method to identify subjects with an infection, disease or other condition
US20060205012A1 (en) 2004-12-09 2006-09-14 Meso Scale Technologies, Llc Diagnostic test
EP2500723B1 (fr) 2006-11-14 2015-07-08 Alere San Diego, Inc. Procédés permettant de surveiller et de prédire le risque du syndrome cardio-rénal
WO2008061149A2 (fr) 2006-11-14 2008-05-22 Biosite Incorporated Procédés et compositions de diagnostic et de pronostic de la sténose d'artère rénale
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US8053198B2 (en) 2007-09-14 2011-11-08 Meso Scale Technologies, Llc Diagnostic methods
WO2010127057A2 (fr) 2009-05-01 2010-11-04 Meso Scale Technologies, Llc. Biomarqueurs de réceptivité thérapeutique
US20120058916A1 (en) 2009-05-13 2012-03-08 Meso Scale Technologies, Llc. Diagnostic methods for liver disorders
WO2013049455A1 (fr) 2011-09-29 2013-04-04 William Blakely Panels et procédés de biodosimétrie
US20130164217A1 (en) 2011-12-21 2013-06-27 Meso Scale Technologies, Llc Method of diagnosing, preventing and/or treating dementia & related disorders
EP2684513A1 (fr) 2012-07-13 2014-01-15 Universite D'angers Procédé pour fournir des tests de diagnostic non invasifs fiables
US20140127730A1 (en) * 2012-11-08 2014-05-08 Veterinary Diagnostics Institute, Inc. Method And System For Detecting Underlying Health Affections Using Biomarkers in Humans and Animals
US20140309263A1 (en) 2013-02-01 2014-10-16 Meso Scale Technologies, Llc Biomarkers of therapeutic responsiveness
US20140221325A1 (en) 2013-02-01 2014-08-07 Meso Scale Technologies, Llc Glomerulonephritis biomarkers
US20140221368A1 (en) 2013-02-01 2014-08-07 Meso Scale Technologies, Llc Biomarkers of therapeutic responsiveness
US20150038365A1 (en) 2013-08-01 2015-02-05 Meso Scale Technologies, Llc Lung cancer biomarkers
EP3762729A1 (fr) 2018-03-08 2021-01-13 Meso Scale Technologies, LLC Marqueurs et/ou biomarqueurs génétiques pour lésion cérébrale traumatique, et dosages ultrasensibles pour biomarqueurs de lésion cérébrale traumatique

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6678669B2 (en) * 1996-02-09 2004-01-13 Adeza Biomedical Corporation Method for selecting medical and biochemical diagnostic tests using neural network-related applications
US6485983B1 (en) * 1999-05-05 2002-11-26 Intec Science, Inc. System for electrochemical quantitative analysis of analytes within a solid phase and affinity chromatographic test strip
WO2001088086A2 (fr) * 2000-04-19 2001-11-22 Multiqtl Ltd. Systeme et procede de cartographie de complexes a caracteres multiples dans des environnements multiples
ATE366939T1 (de) * 2000-04-28 2007-08-15 Bayer Ag Diagnose von leberfibrose mit hilfe von serummarkeralgorithmen
GB0022978D0 (en) * 2000-09-19 2000-11-01 Oxford Glycosciences Uk Ltd Detection of peptides
US20020095260A1 (en) * 2000-11-28 2002-07-18 Surromed, Inc. Methods for efficiently mining broad data sets for biological markers
CA2435254C (fr) * 2001-01-24 2012-05-15 Biowulf Technologies, Llc Procedes d'identification de motifs dans des systemes biologiques et utilisations desdits procedes

Also Published As

Publication number Publication date
WO2004058055A2 (fr) 2004-07-15
WO2004058055A3 (fr) 2005-04-07
EP1588159A4 (fr) 2008-03-12
AU2003300407A1 (en) 2004-07-22
AU2003300407A8 (en) 2004-07-22
EP1588159A2 (fr) 2005-10-26

Similar Documents

Publication Publication Date Title
US20070269836A1 (en) Methods and compositions for the diagnosis of venous thromboembolic disease
US20070224643A1 (en) Methods and compositions for the diagnosis of diseases of the aorta
CA2511482A1 (fr) Methode et systeme de detection de maladies au moyen de combinaisons de marqueurs
US8221995B2 (en) Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20070218498A1 (en) Use of soluble FLT-1 and its fragments in cardiovascular conditions
US20190041403A1 (en) Predicting mortality and detecting severe disease
US7341838B2 (en) Polypeptides related to natriuretic peptides and methods of their identification and use
US20040126767A1 (en) Method and system for disease detection using marker combinations
US20170140122A1 (en) Methods and compositions for monitoring heart failure
US20070092911A1 (en) Methods and compositions for diagnosis and /or prognosis in systemic inflammatory response syndromes
US20080050832A1 (en) Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20040121350A1 (en) System and method for identifying a panel of indicators
US20080118924A1 (en) Use of natriuretic peptides as diagnostic and prognostic indicators in vascular diseases
JP7372251B2 (ja) 末梢動脈疾患、大動脈弁狭窄症についての診断および予後の方法、ならびにアウトカム
US20090004755A1 (en) Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20030219734A1 (en) Polypeptides related to natriuretic peptides and methods of their identification and use
AU2010319290A1 (en) Risk factors and prediction of myocardial infarction
EP2376919B1 (fr) Dosages de peptides natriurétiques combinés
WO2007140188A2 (fr) Utilisation de peptides natriurétiques en tant qu'indicateurs diagnostiques et pronostiques dans des maladies vasculaires

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead